Kashyap Patel elected president of COA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Kashyap Patel was elected president of the Community Oncology Alliance.

Patel, a long-time COA board member, is a full-time practicing medical oncologist and CEO of Carolina Blood and Cancer Care in Rock Hill, South Carolina. He began his one year term Jan. 1.

Patel is board certified in hematology, oncology, and internal medicine. In addition to his work with COA and its committees, he volunteers with other national cancer and quality organizations.

Patel has extensive expertise in value-based care, including having successfully led multiple oncology payment pilots. He has a special interest in health care policy, racial and ethnic disparities, and end of life care.

Miriam Atkins, a practicing medical oncologist at Augusta Oncology in Georgia, was named vice president of the COA board. Debra Patt, a practicing medical oncologist and executive vice president, policy and strategic initiatives at Texas Oncology in Austin, was named secretary of the board.

Emily Touloukian, a practicing medical oncologist and president-elect at Coastal Cancer Center, was also named to the board.

The nominations were completed during a regularly scheduled board meeting on Monday, Dec. 14, 2020. All board of director positions are three-year terms. These new elections became effective Jan. 1, and will end Dec. 31, 2023.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login